RTTNews | Jan 20, 2022 07:25AM EST

07:25 Thursday, January 20, 2022 (RTTNews.com) - CASI Pharmaceuticals Inc. (CASI) said that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its partner BioInvent International AB, for BI-1206, an investigational anti-FcyRllB antibody, for the treatment of follicular lymphoma, the most common form of slow-growing Non-Hodgkin lymphoma or NHL.

In Thursday pre-market trade, CASI was trading at $0.73 up $0.03 or 5.65%.

BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials.

One is evaluating the BI-1206 combination with rituximab for the treatment of Non-Hodgkin lymphoma, which includes patients with follicular lymphoma, MCL and marginal zone lymphoma (MZL) who have relapsed or are refractory to rituximab.

A second Phase 1/2 trial is investigating BI-1206 in combination with anti-PD1 therapy Keytruda (pembrolizumab) in solid tumors.

Read the original article on RTTNews ( https://www.rttnews.com/3256233/casi-pharma-bi-1206-granted-orphan-drug-designation-by-fda-for-follicular-lymphoma-treatment.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved